Loading
A phase 1/2 trial of IBI3014 in advanced solid tumours, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.
IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors. ClinicalTrials.gov record last updated 2026-01-29: recruiting. Enrollment is planned at 250 participants. Primary completion is estimated at 2026-06-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: IBI3014, IBI3014, IBI3014, IBI3014, IBI3014, IBI3014, IBI3014, IBI3014. Registered primary measures: The Safety profile of patients in Phase 1 dose escalation part、Phase 1 dose expansion and Phase 2 dose optimization; Dose limiting toxicity (DLT) of IBI3014 in Phase 1 dose escalation; ORR per RECIST v1.1 in Phase 1 dose expansion and Phase 2 dose optimization.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Innovent Biologics, TROP2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Innovent Biologics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Innovent Biologics and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/